Celgene
Search results
Website. www .bms .com. Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.
Feb 8, 2022 · When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune...
May 15, 2024 · On May 15, 2024, the Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular...
Jan 14, 2022 · Greenberg previously co-founded cell therapy company Juno Therapeutics, which was acquired by Celgene for more than $9 billion in 2018. Co-founder Jak Knowles serves as Affini-T CEO and...
Feb 5, 2021 · February 05, 2021. Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell...
Nov 2, 2017 · SEATTLE-- ( BUSINESS WIRE )-- Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that 15 abstracts detailing updated clinical and preclinical results from the company and its collaborators will be presented at the 59 th American Society of Hema...
Jan 23, 2024 · Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investm
